Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH

Austin G Kulasekararaj, Morag Griffin, Caroline I Piatek, Jamile Shammo, Jun-ichi Nishimura, Christopher J Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jens Peter Panse, Anna Gaya, Yogesh Patel, Peng Liu, Gleb Filippov, Flore Sicre de Fontbrune, Antonio Maria Risitano, Jong Wook Lee

Blood blood.2024026299.

https://doi.org/10.1182/blood.2024026299

Published: 2024

Includes: Supplemental data

Journal Articles

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial

Caroline Piatek, Jong Wook Lee, Morag Griffin, Jun-Ichi Nishimura, Christopher Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jamile Shammo, Anna Gaya, Mohammed Mahdi, Peng Liu, Karl-Johan Myren, Andrew Messali, Flore Sicre de Fontbrune, Jens Panse, Austin G. Kulasekararaj

Blood (2024) 144 (Supplement 1): 2692.

https://doi.org/10.1182/blood-2024-199506

Published: 2024

Journal Articles

Reduced Iron Overload with Pegcetacoplan Treatment in Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria

Jamile Shammo, Michael Yeh, Peter Hillmen, David J Kuter

Blood (2024) 144 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2024-203271

Published: 2024

Journal Articles

A Prospective Trial of Serum Folate Levels in Women with Solid Tumor Malignancies Treated with Olaparib

Laura Owczarzak, Nicole Yun, Lois Anaya Winkelman, Jamile Shammo, Lydia Usha

Blood (2024) 144 (Supplement 1): 5224.

https://doi.org/10.1182/blood-2024-203396

Published: 2024

Journal Articles

Real-World Characteristics and Treatment History of Patients with Paroxysmal Nocturnal Hemoglobinuria Initiating Iptacopan in US Administrative Claims Data

Jamile Shammo, Ver Bilano, Sina Noshad, Lincy Geevarghese, Glorian Yen, Jincy Paulose, Rachael Sorg, Marley Boyd, Allison Keshishian, Sonia Kim, Samantha Tomicki, Soyon Lee

Blood (2024) 144 (Supplement 1): 5681.

https://doi.org/10.1182/blood-2024-203611

Published: 2024

Journal Articles

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data

Austin Kulasekararaj, Morag Griffin, Caroline I Piatek, Jamile Shammo, Jun-Ichi Nishimura, Christopher J. Patriquin, Hubert Schrezenmeier, Anna Gaya, Yogesh Patel, Peng Liu, Gleb Filippov, Flore Sicre De Fontbrune, Antonio M Risitano, Jong-Wook Lee

Blood (2023) 142 (Supplement 1): 576.

https://doi.org/10.1182/blood-2023-189863

Published: 2023

Journal Articles

Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis

Caroline I Piatek, Jong-Wook Lee, Morag Griffin, Jun-Ichi Nishimura, Christopher J. Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jamile Shammo, Anna Gaya, Yogesh Patel, Peng Liu, Karl-Johan Myrén, Flore Sicre De Fontbrune, Jens Panse, Austin Kulasekararaj

Blood (2023) 142 (Supplement 1): 1346.

https://doi.org/10.1182/blood-2023-190015

Published: 2023

Journal Articles

Disease Management and Outcomes in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Analysis of Observational Data from the United States

Jamile Shammo, Sushupta M Vijapur, Josefin Snellman, Jilles M Fermont

Blood (2023) 142 (Supplement 1): 5639.

https://doi.org/10.1182/blood-2023-179896

Published: 2023

Journal Articles

Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib

Stephen T. Oh, Jamile Shammo, Vikas Gupta, Mary Frances McMullin, Prithviraj Bose, Ruben A. Mesa, Alessandro Lucchesi, Sarah Buckley, Purvi Suthar, Karisse Roman-Torres, John Mascarenhas, Francisca Ferrer Marin

Blood (2023) 142 (Supplement 1): 4566.

https://doi.org/10.1182/blood-2023-178753

Published: 2023

Journal Articles

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis

Blood (2020) 135 (19): 1696–1703.

https://doi.org/10.1182/blood.2019003347

Published: 2020

Includes: Supplemental data

Journal Articles

The Transplant Outcomes of a 10/10 Matched Unrelated Donor (MUD) Stem Cell Transplant (SCT) Is Similar to a HLA Identical Related Donor (RD) Transplant.

Catherine Veeder, MD, Sheila Davies, R.N., OCN, Christina Havey, R.N., John J. Maciejewski, MD, PhD, Sunita Nathan, MD, Stephanie A. Gregory, MD, Parameswaran Venugopal, MD, Jamile Shammo, MD, Henry C. Fung, MD

Blood (2009) 114 (22): 4346.

https://doi.org/10.1182/blood.V114.22.4346.4346

Published: 2009

Journal Articles

A Pilot Study Investigating the Safety and Efficacy of Injectable Hemin (Panhematin®) in Patients with Low to Intermediate-1 Risk Myelodysplastic Syndrome.

Jamile Shammo

Blood (2009) 114 (22): 4859.

https://doi.org/10.1182/blood.V114.22.4859.4859

Published: 2009

Journal Articles

The Role of FDG-PET in Hodgkin Lymphoma S/P Autologous Hematopoietic Cell Transplant (HCT) as a Predictor of Outcome.

Neel B. Shah, MD, Mohamed Farhat, M.D., Arti Lakhani, M.D., Daniel Mcfarland, D.O., Parameswaran Venugopal, M.D., Stephanie A Gregory, M.D., Jamile Shammo, M.D., John Maciejewski, M.D., Hande Tuncer, M.D., Henry C Fung, M.D.

Blood (2008) 112 (11): 2178.

https://doi.org/10.1182/blood.V112.11.2178.2178

Published: 2008

Journal Articles

Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment.

Hagop Kantarjian, Pierre Fenaux, Mikkael A. Sekeres, Pamela Becker, Adam Boruchov, David Bowen, Richard Larson, Roger Lyons, Petra Muus, Jamile Shammo, Michael Ehrman, Kuolung Hu, Janet Nichol

Blood (2007) 110 (11): 250.

https://doi.org/10.1182/blood.V110.11.250.250

Published: 2007

Journal Articles

Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS).

Lubomir Sokol, MD, PhD, Larry Cripe, M.D., Hagop Kantarjian, M.D., Mikkael A. Sekeres, M.D., Simrit Parmar, M.D., Peter Greenberg, M.D., Stuart Goldberg, M.D., Vikas Bhushan, M.D., Jamile Shammo, M.D., Raymond Hohl, M.D., Ph.D., Yu-Ping Li, Ph.D., Ann Lowe, M.D., Joy Zhu, M.D., Alan List, M.D.

Blood (2006) 108 (11): 2657.

https://doi.org/10.1182/blood.V108.11.2657.2657

Published: 2006

Journal Articles

Immune Ablation Using High-Dose Cyclophosphamide without Stem Cell Rescue for Intractable Multiple Sclerosis.

Jamile Shammo, MD, Stacey E. Ban, MD, George Katsamakis, MD, Dusan Stefoski, MD, Michael Ko, MD, Carlene Porter, RN, NP, Sharon Manson, RN, NP, Stephanie A. Gregory, MD

Blood (2005) 106 (11): 5504.

https://doi.org/10.1182/blood.V106.11.5504.5504

Published: 2005

Journal Articles

Rituximab (Rituxan) Combined with ESHAP Chemotherapy Is Highly Active in Relapsed/ Refractory Aggressive Non-Hodgkin’s Lymphoma.

Parameswaran Venugopal, MD, Stephanie A. Gretory, MD, John Showel, MD, Jamile Shammo, MD, Sari Enschede, MD, Melissa Larson, MD, Teresa Obrien, RN, Tatiana D. Sokolovsky, Aaron Means

Blood (2004) 104 (11): 4636.

https://doi.org/10.1182/blood.V104.11.4636.4636

Published: 2004

Journal Articles

Radioimmunotherapy with I 131 Tositumomab in Relapsed and Transformed Low-Grade (LG) Non-Hodgkin’s Lymphoma (NHL): Long-Term Follow-Up of a Single Institution Experience.

Huma Qawi, Teresa M. O’Brien, Parameswaran Venugopal, Jamile Shammo, Elena Bogdanova, Stephanie A. Gregory

Blood (2004) 104 (11): 4641.

https://doi.org/10.1182/blood.V104.11.4641.4641

Published: 2004

NARROW

Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial

Reduced Iron Overload with Pegcetacoplan Treatment in Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria

A Prospective Trial of Serum Folate Levels in Women with Solid Tumor Malignancies Treated with Olaparib

Real-World Characteristics and Treatment History of Patients with Paroxysmal Nocturnal Hemoglobinuria Initiating Iptacopan in US Administrative Claims Data

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data

Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis

Disease Management and Outcomes in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Analysis of Observational Data from the United States

Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis

The Transplant Outcomes of a 10/10 Matched Unrelated Donor (MUD) Stem Cell Transplant (SCT) Is Similar to a HLA Identical Related Donor (RD) Transplant.

A Pilot Study Investigating the Safety and Efficacy of Injectable Hemin (Panhematin®) in Patients with Low to Intermediate-1 Risk Myelodysplastic Syndrome.

The Role of FDG-PET in Hodgkin Lymphoma S/P Autologous Hematopoietic Cell Transplant (HCT) as a Predictor of Outcome.

Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment.

Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS).

Immune Ablation Using High-Dose Cyclophosphamide without Stem Cell Rescue for Intractable Multiple Sclerosis.

Rituximab (Rituxan) Combined with ESHAP Chemotherapy Is Highly Active in Relapsed/ Refractory Aggressive Non-Hodgkin’s Lymphoma.

Radioimmunotherapy with I 131 Tositumomab in Relapsed and Transformed Low-Grade (LG) Non-Hodgkin’s Lymphoma (NHL): Long-Term Follow-Up of a Single Institution Experience.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only